Targeting the Novel Immune Checkpoint KLRG1 is Markedly Therapeutic Against Cancer Through Multiple Lymphocyte Subsets
Favorite
Share
More Options
14

Open in WPS to view all 14 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
